0.58
-0.126(-17.82%)
Currency In USD
| Previous Close | 0.71 |
| Open | 0.71 |
| Day High | 0.72 |
| Day Low | 0.58 |
| 52-Week High | 2.74 |
| 52-Week Low | 0.36 |
| Volume | 2.38M |
| Average Volume | 1.24M |
| Market Cap | 69.71M |
| PE | -0.63 |
| EPS | -0.92 |
| Moving Average 50 Days | 0.77 |
| Moving Average 200 Days | 0.77 |
| Change | -0.13 |
If you invested $1000 in Invivyd, Inc. (IVVD) since IPO date, it would be worth $29.28 as of August 18, 2025 at a share price of $0.611. Whereas If you bought $1000 worth of Invivyd, Inc. (IVVD) shares 3 years ago, it would be worth $135.54 as of August 18, 2025 at a share price of $0.611.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)
GlobeNewswire Inc.
1 hours ago
New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA® (pemivibart) against XFG Centers for Disease Control data and wastewater surveillance data indicate XFG variant appears to be driving a growing wave of COV
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19
GlobeNewswire Inc.
Aug 14, 2025 8:47 PM GMT
Alignment follows Type C meeting for VYD2311 as previously disclosed BLA pathway for VYD2311 to be supported by a single, Phase 2/3 randomized, double-blind, placebo-controlled trial with a primary endpoint of reduction in symptomatic COVID-19, resem
Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome
GlobeNewswire Inc.
Jul 23, 2025 11:01 AM GMT
WALTHAM, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced the addition of Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale School of Medicine, to the SPEAR (Spike Protein Elimination and Recovery) Study